SCHEMBL5723699

SCHEMBL5723699

CCOC(=O)CC1COc2c(OC)ccc(C(=O)O)c21

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 2/20 0.35
MAPT P10636 2/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
CYP1A2 P05177 1/20 0.34
GLA P06280 1/20 0.34
POLB P06746 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
PLIN1 O60240 1/20 0.34
PLIN5 Q00G26 1/20 0.34
ABHD5 Q8WTS1 1/20 0.34
FFAR1 O14842 1/20 0.34
OPRM1 P35372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6839358 0.86 LMNA (0.35) LMNAALDH1A1KDM4EHSD17B10TDP1
SCHEMBL5723232 0.85 SMN1; SMN2 (0.40) LMNAALDH1A1KDM4EMAPTMEN1
SCHEMBL5722912 0.85 KDM4E (0.43) LMNAALDH1A1KDM4EHSD17B10TDP1
SCHEMBL5723139 0.83 KDM4E (0.42) LMNAALDH1A1KDM4EHSD17B10TDP1
SCHEMBL5722704 0.82 ALDH1A1 (0.45) LMNAALDH1A1KDM4ECNR2
SCHEMBL6833282 0.80 PDE4D (0.52)
SCHEMBL5722788 0.80 NPC1 (0.48) LMNAALDH1A1KDM4EPOLBMEN1
SCHEMBL5723061 0.80 PDE4D (0.50)
SCHEMBL5723212 0.76 KDM4E (0.47) LMNAALDH1A1KDM4EHSD17B10TDP1
SCHEMBL5722857 0.75 SGMS2 (0.42) LMNAALDH1A1KDM4EHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0771794-B1 OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS KYOWA HAKKO KOGYO KK (JP) 2006-05-03 EP disclosed
US-6716987-B1 PHOSPHODIESTERASE IV INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-04-06 US disclosed
US-6514996-B2 Derivatives of benzofuran or benzodioxole KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-02-04 US disclosed
US-20020128290-A1 DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-09-12 US disclosed
EP-0771794-A1 OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS KYOWA HAKKO KOGYO CO., LTD. (JP) 1997-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128290-A1 DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE CBR1, CBR3, CYC1 LMNA 1848/4885ALDH1A1 323/4885KDM4E 3975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.